[Kavita]

Discuss about alexion pharmaceuticals miami fl here. Welcome to Courses.ind.in and this page is for alexion pharmaceuticals miami fl discussion. If you are looking for information on alexion pharmaceuticals miami fl then ask your question is as much details as possible in the “Reply” box provided below. The more detailed your question will be, the more easy will it be for our experts to answers your query. And if you have any updated or latest information on alexion pharmaceuticals miami fl, then please share you knowledge with our experts in the “Reply” box below. Your reply will be published here and your knowledge can help many people. Thanks for stopping by at Courses.ind.in. Please visit again.

Hi I would like to have the details of the Alexion Pharmaceuticals as well as the contact address of the office of Alexion Pharmaceuticals located in Miami, Florida?

[Vishal Kotkar]

Alexion is a worldwide biopharmaceutical organization concentrated on creating and conveying life-changing treatments for patients with annihilating and uncommon infections.

Patients with these life-undermining infections frequently have no powerful treatment alternatives, and they and their families endure with little expectation. It will likely convey therapeutic achievements where none as of now exist. It is driven on the grounds that it knows individuals' lives rely on upon the work.

Breakthrough Products

Alexion created Soliris® (eculizumab), the worlds initially endorsed terminal supplement inhibitor, from the lab through commercialization.

Today, Soliris is endorsed in almost 50 nations for the treatment of patients with paroxysmal nighttime hemoglobinuria (PNH) and in more than 40 nations for the treatment of patients with atypical hemolytic uremic disorder (aHUS) — two life-undermining, ultra-uncommon disarranges brought on by uncontrolled supplement enactment.

As the worldwide pioneer in supplement restraint, Alexion is fortifying and expanding its arrangement of supplement inhibitors, including assessing potential signs for eculizumab in extra serious and ultra-uncommon clutters.

Alexion's metabolic establishment incorporates two exceedingly creative catalyst supplanting treatments for patients with life-debilitating and ultra-uncommon clutters: Strensiq® (asfotase alfa) is affirmed for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) is endorsed for patients with lysosomal corrosive lipase lack (LAL-D).

A Global Leader in Rare Diseases

Alexion was built up in the U.S. in 1992 and turned into an open organization in 1996 (NASDAQ: ALXN). It has added to the NASDAQ-100 Index in 2011 and to the Standard and Poor's 500 Index in 2012. Our worldwide central command and research operations are in New Haven, Conn. Alexion's roughly 3,000 representatives around the globe serve patients in 50 nations.

Research and Development



Address:

Alexion Pharmaceuticals
800 Brickell Ave,
Miami,
FL 33131,
USA
Phone: +1 305-371-3171